Pieris Pharmaceuticals, Inc. (PIRS)

Oncology Corporate Profile

Stock Performance

2.0500
-0.1500

HQ Location

255 State Street
Boston, MA 2109

Company Description

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumour micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia.

Website: http://www.pieris.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PRS-343CD137/HER2 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.pieris.com

Recent News Headlines

Pieris Pharmaceuticals Reports Full-Year 2016 Financial Results and Corporate Update

3/23/2017 12:01 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported ...

Pieris Pharmaceuticals to Host Full-Year 2016 Investor Call And Corporate Update on March 23, 2017

3/15/2017 11:03 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a Full-Year 2016 Investor Call on Thursday, March 23, 2017 at 10:00 AM ...

Pieris Pharmaceuticals to Present at Oppenheimer's 27th Annual Healthcare Conference, Wednesday, March 22nd at 11:30 am EDT

3/14/2017 11:03 am

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Pharmaceuticals to Present at the 29th Annual Roth Conference Monday, March 13th at 2:00 pm PST

3/7/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Pharmaceuticals Announces Presentation of IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, at the 2017 Meeting of the American Association for Cancer Research (AACR)

3/6/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today that a set of ex vivo and in ...

Pieris Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6th at 4:40 pm EST

3/1/2017 01:00 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical

2/27/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that it has granted ASKA Pharmaceutical ...

Pieris Pharmaceuticals to Present at the Bio CEO Investor Conference on February 13th at 1:30 pm EST

2/8/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today that President and CEO Stephen Yoder will present a corporate overview ...

Pieris Announces Management Transition

2/7/2017 10:02 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, today announced that Darlene Deptula-Hicks ...

Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration

1/5/2017 12:03 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced it ...

Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance

1/5/2017 12:00 pm

[Marketwired] - Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including ...

Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

12/1/2016 01:00 pm

[Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced ...